Comparative Pharmacology
Head-to-head clinical analysis: INVANZ versus VABOMERE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: INVANZ versus VABOMERE.
INVANZ vs VABOMERE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Ertapenem is a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), leading to cell death.
Vabomere is a combination of meropenem, a carbapenem antibiotic that inhibits bacterial cell wall synthesis by binding to penicillin-binding proteins (PBPs), and vaborbactam, a beta-lactamase inhibitor that protects meropenem from degradation by certain serine beta-lactamases, including extended-spectrum beta-lactamases (ESBLs) and Klebsiella pneumoniae carbapenemase (KPC).
1 g IV or IM once daily
Vabomere (meropenem and vaborbactam) 4 g (meropenem 2 g and vaborbactam 2 g) intravenously every 8 hours infused over 3 hours.
None Documented
None Documented
Terminal elimination half-life approximately 4 hours; prolonged to approximately 8 hours in mild to moderate renal impairment (CrCl 30-59 mL/min) and to 14 hours in severe renal impairment (CrCl <30 mL/min); clinical context: requires dosage adjustment in renal impairment.
The terminal elimination half-life is approximately 1 hour for meropenem and 2 hours for vaborbactam in patients with normal renal function. This short half-life supports three-times-daily dosing in patients with creatinine clearance ≥50 mL/min.
Renal: ~80% unchanged in urine; biliary/fecal: ~10% as unchanged drug and the open-ring metabolite; minor hepatic metabolism.
Vabomere (meropenem and vaborbactam) is primarily excreted renally. Approximately 40-50% of meropenem and 75-95% of vaborbactam are excreted unchanged in urine. Biliary/fecal excretion is minimal (<2% for both).
Category C
Category C
Carbapenem Antibiotic
Carbapenem Antibiotic